Global Duchenne Muscular Dystrophy Drugs Market Overview And Scope:
Global Duchenne Muscular Dystrophy Drugs Market Size was estimated at USD 1632.42 million in 2022 and is projected to reach USD 7589.01 million by 2028, exhibiting a CAGR of 29.19% during the forecast period.
The Global Duchenne Muscular Dystrophy Drugs Market Report 2023 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Duchenne Muscular Dystrophy Drugs utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2023 and 2030. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Akashi Therapeutics Inc, Antisense Therapeutics Ltd, Beech Tree Labs Inc, Biogen Inc, Bioleaders Corp, BioMarin Pharmaceutical Inc, Biophytis SAS, Capricor Therapeutics Inc, Catabasis Pharmaceuticals Inc, CRISPR Therapeutics, Cumberland Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Debiopharm International SA, Editas Medicine Inc, Eloxx Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, FibroGen Inc, Fulcrum Therapeutics Inc, Galapagos NV, Genethon SA, GTx Inc, Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc, SOM Biotech SL, Strykagen Corp, Summit Therapeutics Plc, Taiho Pharmaceutical Co Ltd, Teijin Pharma Ltd, WAVE Life Sciences Ltd
Global Duchenne Muscular Dystrophy Drugs Market Segmentation
By Type, Duchenne Muscular Dystrophy Drugs market has been segmented into:Development and Drug Target
Mechanism of Action (MoA)
Route of Administration (RoA)
Molecule Type
By Application, Duchenne Muscular Dystrophy Drugs market has been segmented into:
Hospitals and Clinics
Medical Laboratories
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Duchenne Muscular Dystrophy Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Duchenne Muscular Dystrophy Drugs market.
Top Key Players Covered in Duchenne Muscular Dystrophy Drugs market are:
Akashi Therapeutics Inc
Antisense Therapeutics Ltd
Beech Tree Labs Inc
Biogen Inc
Bioleaders Corp
BioMarin Pharmaceutical Inc
Biophytis SAS
Capricor Therapeutics Inc
Catabasis Pharmaceuticals Inc
CRISPR Therapeutics
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
FibroGen Inc
Fulcrum Therapeutics Inc
Galapagos NV
Genethon SA
GTx Inc
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics Inc
SOM Biotech SL
Strykagen Corp
Summit Therapeutics Plc
Taiho Pharmaceutical Co Ltd
Teijin Pharma Ltd
WAVE Life Sciences Ltd
Objective to buy this Report:
1. Duchenne Muscular Dystrophy Drugs analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Duchenne Muscular Dystrophy Drugs market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Duchenne Muscular Dystrophy Drugs Market by Type
5.1 Duchenne Muscular Dystrophy Drugs Market Overview Snapshot and Growth Engine
5.2 Duchenne Muscular Dystrophy Drugs Market Overview
5.3 Development and Drug Target
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2030F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Development and Drug Target: Geographic Segmentation
5.4 Mechanism of Action (MoA)
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2030F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Mechanism of Action (MoA): Geographic Segmentation
5.5 Route of Administration (RoA)
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2030F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Route of Administration (RoA): Geographic Segmentation
5.6 Molecule Type
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2016-2030F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Molecule Type: Geographic Segmentation
Chapter 6: Duchenne Muscular Dystrophy Drugs Market by Application
6.1 Duchenne Muscular Dystrophy Drugs Market Overview Snapshot and Growth Engine
6.2 Duchenne Muscular Dystrophy Drugs Market Overview
6.3 Hospitals and Clinics
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2030F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospitals and Clinics: Geographic Segmentation
6.4 Medical Laboratories
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2030F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Medical Laboratories: Geographic Segmentation
6.5 Others
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2030F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Others: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Duchenne Muscular Dystrophy Drugs Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Duchenne Muscular Dystrophy Drugs Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Duchenne Muscular Dystrophy Drugs Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 AKASHI THERAPEUTICS INC
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 ANTISENSE THERAPEUTICS LTD
7.4 BEECH TREE LABS INC
7.5 BIOGEN INC
7.6 BIOLEADERS CORP
7.7 BIOMARIN PHARMACEUTICAL INC
7.8 BIOPHYTIS SAS
7.9 CAPRICOR THERAPEUTICS INC
7.10 CATABASIS PHARMACEUTICALS INC
7.11 CRISPR THERAPEUTICS
7.12 CUMBERLAND PHARMACEUTICALS INC
7.13 DAIICHI SANKYO CO LTD
7.14 DEBIOPHARM INTERNATIONAL SA
7.15 EDITAS MEDICINE INC
7.16 ELOXX PHARMACEUTICALS INC
7.17 F. HOFFMANN-LA ROCHE LTD
7.18 FIBROGEN INC
7.19 FULCRUM THERAPEUTICS INC
7.20 GALAPAGOS NV
7.21 GENETHON SA
7.22 GTX INC
7.23 SANTHERA PHARMACEUTICALS HOLDING AG
7.24 SAREPTA THERAPEUTICS INC
7.25 SOM BIOTECH SL
7.26 STRYKAGEN CORP
7.27 SUMMIT THERAPEUTICS PLC
7.28 TAIHO PHARMACEUTICAL CO LTD
7.29 TEIJIN PHARMA LTD
7.30 WAVE LIFE SCIENCES LTD
Chapter 8: Global Duchenne Muscular Dystrophy Drugs Market Analysis, Insights and Forecast, 2016-2030
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Development and Drug Target
8.2.2 Mechanism of Action (MoA)
8.2.3 Route of Administration (RoA)
8.2.4 Molecule Type
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospitals and Clinics
8.3.2 Medical Laboratories
8.3.3 Others
Chapter 9: North America Duchenne Muscular Dystrophy Drugs Market Analysis, Insights and Forecast, 2016-2030
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Development and Drug Target
9.4.2 Mechanism of Action (MoA)
9.4.3 Route of Administration (RoA)
9.4.4 Molecule Type
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospitals and Clinics
9.5.2 Medical Laboratories
9.5.3 Others
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Duchenne Muscular Dystrophy Drugs Market Analysis, Insights and Forecast, 2016-2030
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Development and Drug Target
10.4.2 Mechanism of Action (MoA)
10.4.3 Route of Administration (RoA)
10.4.4 Molecule Type
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospitals and Clinics
10.5.2 Medical Laboratories
10.5.3 Others
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Duchenne Muscular Dystrophy Drugs Market Analysis, Insights and Forecast, 2016-2030
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Development and Drug Target
11.4.2 Mechanism of Action (MoA)
11.4.3 Route of Administration (RoA)
11.4.4 Molecule Type
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospitals and Clinics
11.5.2 Medical Laboratories
11.5.3 Others
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Duchenne Muscular Dystrophy Drugs Market Analysis, Insights and Forecast, 2016-2030
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Development and Drug Target
12.4.2 Mechanism of Action (MoA)
12.4.3 Route of Administration (RoA)
12.4.4 Molecule Type
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospitals and Clinics
12.5.2 Medical Laboratories
12.5.3 Others
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Analysis, Insights and Forecast, 2016-2030
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Development and Drug Target
13.4.2 Mechanism of Action (MoA)
13.4.3 Route of Administration (RoA)
13.4.4 Molecule Type
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospitals and Clinics
13.5.2 Medical Laboratories
13.5.3 Others
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Duchenne Muscular Dystrophy Drugs Market Analysis, Insights and Forecast, 2016-2030
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Development and Drug Target
14.4.2 Mechanism of Action (MoA)
14.4.3 Route of Administration (RoA)
14.4.4 Molecule Type
14.5 Historic and Forecasted Market Size By Application
14.5.1 Hospitals and Clinics
14.5.2 Medical Laboratories
14.5.3 Others
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Duchenne Muscular Dystrophy Drugs Scope:
|
Report Data
|
Duchenne Muscular Dystrophy Drugs Market
|
|
Duchenne Muscular Dystrophy Drugs Market Size in 2025
|
USD XX million
|
|
Duchenne Muscular Dystrophy Drugs CAGR 2025 - 2032
|
XX%
|
|
Duchenne Muscular Dystrophy Drugs Base Year
|
2024
|
|
Duchenne Muscular Dystrophy Drugs Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Akashi Therapeutics Inc, Antisense Therapeutics Ltd, Beech Tree Labs Inc, Biogen Inc, Bioleaders Corp, BioMarin Pharmaceutical Inc, Biophytis SAS, Capricor Therapeutics Inc, Catabasis Pharmaceuticals Inc, CRISPR Therapeutics, Cumberland Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Debiopharm International SA, Editas Medicine Inc, Eloxx Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, FibroGen Inc, Fulcrum Therapeutics Inc, Galapagos NV, Genethon SA, GTx Inc, Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc, SOM Biotech SL, Strykagen Corp, Summit Therapeutics Plc, Taiho Pharmaceutical Co Ltd, Teijin Pharma Ltd, WAVE Life Sciences Ltd.
|
|
Key Segments
|
By Type
Development and Drug Target
Mechanism of Action (MoA)
Route of Administration (RoA)
Molecule Type
By Applications
Hospitals and Clinics
Medical Laboratories
Others
|
